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Abstract
BACKGROUND: Radiolabelled human recombinant insulin can
be used for the imaging of insulin receptors in some tumours
where FDG has natural uptake and diminishes the value of its
imaging.
MATERIAL AND METHODS: Insulin was successively labelled
with [67Ga]-gallium chloride after conjugation with freshly pre-
pared cyclic DTPA-dianhydride (HPLC radiochemical purity
assay > 96%) followed by biodistribution studies in normal rats,
white blood cell labelling and preliminary SPECT studies.
RESULTS: In vitro studies demonstrated the retention of ra-
diolabelled insulin receptor affinity using freshly prepared hu-
man white blood cells at different blood sugar conditions.
Preliminary in vivo studies in a normal rat model was per-
formed to determine the biodistribution of the radioimmuno-
conjugate at up to 44 h. SPECT images revealed high up-
take of the liver.
CONCLUSION: Radiolabelled insulin is stable enough to be
used in biological studies in order to image insulin receptors in
diabetic conditions as well as possible tumour imaging appli-
cations. The data was consistent with other radiolabelled insu-
lin studies.
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Introduction
The metabolism of glucose has been an interesting target for
tumour imaging for three decades. The development of radiola-
belled glucose by many research groups in the 1970s and 1980s
presented the most common PET radiopharmaceutical, 18F-FDG.
Since then FDG has been used in the detection and staging of
several malignancies. Few limitations have been proposed in the
last few years in using FDG as a tracer, including natural accumu-
lation of the tracer in the bladder, liver and brain, which can limit
the detection of malignancies of these regions.
Insulin (Figure 1) has been radiolabelled with many SPECT
and PET radionuclides such as 99mTc [1], 123I [2, 3], 18F [4, 5] for
various purposes, such as the study of insulin biodistribution in
diabetic subjects [6] and over-expression of insulin receptor on
the surface of IM-9 lymphoblastoid tumour cells [7].
In order to obtain an insulin conjugate for use in diagnostic
studies using metallic PET or SPECT radioisotopes, 67Ga-labelled
insulin was prepared for preliminary biodistribution studies, based
on our recent experiences on the preparation of radiometal-la-
belled proteins [8]. Radiolabelled protein was injected intravenously
into the tail vein of normal rats and the biodistribution of the tracer
was checked among the tissues.
Material and methods
Production of 67Ga was performed at the Nuclear Research
Centre for Agriculture and Medicine (NRCAM) using a 30 MeV
cyclotron (Cyclone-30, IBA). Enriched zinc-68 chloride with en-
richment of > 95% was obtained from the Ion Beam Separa-
tion Department at NRCAM. Sephadex G-50, sodium acetate,
phosphate buffer components, methanol and ammonium ace-
tate were purchased from the Sigma-Aldrich Chemical Co.
(U.K.). Cyclic DTPA dianhydride was freshly prepared and kept
under a blanket of N2. The insulin was a pharmaceutical sam-
ple purchased from Roche Co. and was used without further
purification. Thin layer chromatography (TLC) of non-radioac-
tive products was performed on polymer-backed silica gel
(F 1500/LS 254, 20 ¥ 20 cm, TLC Ready Foil, Schleicher &
Schuell®). Mixtures of ammonium acetate/10%-methanol (50:50
or 90:10) were used as eluent. Radio-chromatography was
performed by counting different 5 mm slices of polymer-backed
silica gel paper using a high purity germanium (HPGe) detec-
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tor coupled with a Canberra‘ (model GC1020–7500SL) multi-
channel analyzer. Calculations were based on the 184 keV peak
for 67Ga. All values were expressed as mean ± standard devia-
tion (mean ± SD) and the data were compared using student
T-test. Statistical significance was defined as P < 0.05. Animal
studies were performed in accordance with the United King-
dom Biological Council’s Guidelines on the Use of Living Ani-
mals in Scientific Investigations, 2nd edn.
Radiolabelling of the antibody conjugate with 67Ga
The antibody DTPA-conjugate was labelled using an optimi-
zation protocol according to literature [9, 10]. Typically, 37–40
MBq of 67Ga-chloride (in 0.2 M HCl) was added to a conical vial
and dried under a flow of nitrogen. To the Ga-containing vial,
conjugated fraction was added in 1 ml of phosphate buffer (0.1 M,
pH = 8) and mixed gently for 30 seconds. The resulting solution
was incubated at room temperature for 30 minutes. Following
incubation, the radiolabelled antibody conjugate was checked
using ITLC/HPLC methods for chemical and radiochemical puri-
ty. If the percentage of impurities was more than 10%, the sam-
ple was purified using gel filtration as follows. Briefly, the radiola-
belled mixture was passed through a Sephadex G-50 column
(2 ¥ 15 cm, 2 g in 50 ml of Milli-Q® water) separately, and one-
millilitre fractions were collected and checked for the presence
of protein using UV absorbance at 280 nm or visible folin-phenol
colorimetric assay. Control labelling experiments were also per-
formed using 67GaCl3, and DTPA with 
67GaCl3. High performance
liquid chromatography (HPLC) was performed on the final prep-
aration using acetate buffer solution (50 mM pH. 5.5) as eluent
(flow rate: 1 ml/min pressure: 130 KgF/cm2) for 20 min in order
to elute low molecular weight components (Figure 2). Radiola-
belled peptide was eluted using a gradient of the latter solution
(100 to 0%) and citrate buffer solution (50 mM, pH.4, 0 to 100%)
using reverse stationary phase.
Stability testing of the radiolabelled compound
in presence of serum
Labelled compound stability in serum was assessed by gel
filtration on a Sepharose column (1 ¥ 30 cm). The column was
equilibrated with PBS and eluted at a flow rate of 0.5 ml/min at
room temperature; 0.5 ml fractions were collected.
White blood cell affinity experiment
Due to the adsorption of insulin in the surface of white blood
cells for glucose consumption [11], these cells were used to de-
termine the retention of insulin biological activity using the report-
ed method for insulin cell affinity with slight modifications [2]. In
a typical run, healthy male volunteer blood samples (3 ml) were
collected in sterile polymer tubes with added anticoagulant. The
samples were centrifuged at 3000 rpm for five minutes then the
serum was discarded. The cell pellets were reconstituted in 1 ml
of PBS followed by the addition of the 67Ga-DTPA-insulin final so-
lution (3 MBq). The samples were kept at 37∞C for up to 2.5 hours.
One-millilitre samples were taken at various time intervals (30, 60,
90, 150) and centrifuged at 3000 rpm for 5 min. The cell pellets
were carefully washed with PBS and the washing solution was
discarded. The area under the curve of the 184 keV peak was de-
termined for samples (cell pellet and the supernatants) using an
HPGe detector for 50 seconds and the ratio of cell/
/supernatants+cell was determined (n = 5).
Biodistribution of 67Ga-DTPA-insulin in normal rats
To determine its biodistribution, 67Ga-DTPA-insulin was ad-
ministered to normal rats. A volume (50 ml) of final 67Ga-DTPA-
-insulin solution containing 1.48 ± 0.07 MBq (40 ± 2 mCi) radioac-
tivity was injected intravenously into rats through their tail vein.
Figure 1. Structure of human insulin.
Figure 2. HPLC chromatogram of final radiolabelled solution on a reversed
phase column using a gradient of acetate/citrate buffer.
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The animals were sacrificed at exact time intervals (2, 3, 21.5 and
44 h), and the %ID/g of different organs was calculated as the
percentage of injected dose (based on area under the curve of
184 keV peak) per gram using an HPGe detector.
Total blood cell labelling
The binding of the radiolabelled insulin to the superficial insu-
lin receptors on the white blood cells was determined using a cell
tagging protocol. Briefly, a blood sample (5 ml) was taken from a
male volunteer followed by centrifugation at 3000 rpm for five min-
utes. The supernatant was decanted and the separated blood
cell pellet was washed three times by PBS (3 ¥ 5 ml, pH. 7.4). The
pellet was then gently re-suspended in PBS at 37∞C using mild
shaking. Then, radiolabelled insulin (3.7 MBq, 50–100 ml) was added
to the cell suspension and kept at body temperature in an incuba-
tor with mild shaking. At specific time intervals, one millilitre of the
suspension was collected and centrifuged at 3000 rpm for five
minutes and the radioactive counts for the supernatant, cell pellet
and whole mixture were determined in a dose calibrator. The con-
trol tests were performed using free 67Ga3+ and 67Ga-DTPA to
minimize the effect of any unspecific labelling in exactly the same
manner. The uptake ratio was determined as the amount of cen-
trifuged cell mixture radioactivity per total initial activity used.
SPECT imaging of 67Ga-DTPA-insulin in normal rats
Images were taken at 24 and 48 hours after administration of
the radiopharmaceutical by a dual-head SPECT system. The mouse-
to-high energy septa distance was 12 cm. The useable field of view
(UFOV) was 540 mm ¥ 400 mm. The spatial resolution in the coin-
cidence mode was 10 mm FWHM at the CFOV. Sixty-four projec-
tions were acquired for 30 seconds per view with a 64 ¥ 64 matrix.
Results and discussion
Conjugation of insulin with DTPA cyclic
di-anhydride and radiolabelling of insulin with 67Ga
The labelling yield of 67Ga-DTPA-insulin was studied in a wide
range of insulin/DTPA ratios in order to optimize the process and
to improve 67Ga-DTPA-insulin performance in vitro.
The mixture was finally tested by HPLC in order to determine
the radiochemical purity before administration to rodent models
for biodistribution studies. Figure 3 shows the HPLC chromato-
gram of 67GaDTPA and the final solution. The fast eluting compo-
nent (4.28 min) was shown to be a mixture of free 67Ga and 67GaDT-
PA, which were washed out on reverse phase stationary phase.
Both compounds are ionic, so they are eluted at the same reten-
tion time. The radiolabelled protein was finally washed out at 17.2
minutes.
Stability of radiolabelled protein in vitro
The stability of the radiolabelled protein in vitro was determined
after a challenge with phosphate-buffered saline and serum. ITLC
analysis showed that the proteins retained the radiolabel over a
period of several hours, indicating that the Ga-protein chelate was
of high affinity.
These results were confirmed by gel filtration chromatogra-
phy. After incubation of [67Ga]-DTPA-insulin with PBS for two hours,
almost all of the radioactivity eluted in the same position as [67Ga]-
DTPA-insulin; there was no evidence for large-scale release of
free Ga. Similarly, gel filtration chromatography of 67Ga-DTPA-in-
sulin after a two-hour incubation with human serum showed that
the radioactivity still eluted in the same position. Thus, there was
no evidence for either degradation or transchelation of 67Ga to
other serum proteins over a period consistent with the normal blood
clearance time of insulin.
Biodistribution studies
The distribution of [67Ga]-DTPA-insulin among tissues was
determined for untreated rats. A volume (0.1 ml) of final [67Ga]-
-DTPA-insulin solution containing 4.4–5.2 MBq radioactivity (6 mg
protein in 100 mL) was injected into the dorsal tail vein. The
total amount of radioactivity injected into each mouse was mea-
sured by counting the 1 ml syringe before and after injection in
a dose calibrator with a fixed geometry. The animals were sac-
rificed by ether asphyxiation at selected times after injection
(2, 3, 21.5 and 44 h), the tissues (blood, heart, spleen, kidneys,
liver, intestine, stomach, lung, skin) and faeces were weighed
and their accumulated activities were determined with a g-ray
Figure 3. Percentage of injected dose per gram (%ID/g) of 67Ga-DTPA-insulin in normal rat tissues 3–44 h post injection.
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Figure 4. Radiolabelled insulin blood cell affinity determination as a func-
tion of time in normally fed (series 1), well fed (series 2) and fasting male
volunteers (series 3).
in mice serum for at least 24 hours and no significant amount of
free 67Ga or 67Ga-DTPA was observed. Trace amounts of 67Ga-
gallium chloride (ª 1%) were detected by TLC. The final prepa-
ration was administered to normal rats, and the biodistribution
of the radiopharmaceutical was checked one and six hours lat-
er. [67Ga]-DTPA-insulin is a good probe for the imaging of insulin
receptors.
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